Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Closes $2.1M Offering

NEW YORK (GenomeWeb) – Great Basin Scientific said today that it has closed a previously announced registered offering of 8.9 million units, raising $2.1 million in net proceeds.

Roth Capital Partners acted as the exclusive placement agent for the offering, which comprised Class A units, offered at $.30 per unit, and Class B units, offered at $.29 per unit.  

Class A units consisted of one share of Great Basin's common stock and one Series J warrant to purchase 2.5 shares of the firm's common stock at $.30 apiece.

Purchasers of the Class A units were offered Class B units if their purchase of the Class A units would result in the ownership of more than 4.99 percent or 9.99 percent, at the purchaser's election, of Great Basin's issued and outstanding common stock, after the completion of the offering.

Class B units were made up of one prefunded Series K warrant to purchase one share of common stock at $.30 and one Series J warrant.

Great Basin said it intends to use the proceeds for research and development, sales and marketing expenses, the redemption of certain notes, and general corporate purposes.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.